Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis is a chronic skin condition characterized by inflamed, itchy, and red skin. It often leads to discomfort and can significantly impact daily life.
Atopic Dermatitis in Children: Abrocitinib Study
We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 6 and 12 years old?
- Do you weigh at least 15 kg?
- Do you have a documented diagnosis of moderate-to-severe eczema (atopic dermatitis)?
- Have you had any skin infections that required treatment in the last 2 weeks?
- Have you ever been treated with a systemic JAK inhibitor for eczema?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Abrocitinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Technische Universitaet Dresden
Klinik und Poliklinik für Dermatologie
Dresden, Germany
Universitaet Muenster
Klinik für HautkrankheitenHautklinik, Zentrale Studienkoordination für innovative Dermatologie ZiD
Münster, Germany
Clinexpert Kft.
Budapest, Hungary
Sponsor: Pfizer Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.